Prediction of the Potential of Active Compounds in Kratom Leaves (Mitragyna speciosa) as Anti-Inflammatory Candidates through a Molecular Docking Approach to COX-1, COX-2, TNF-α, and IL-1β
Main Article Content
Page: 3031-3042
Abstract
Inflammation is a central component of numerous pathological conditions, and the limitations of currently available anti-inflammatory therapies continue to motivate the search for structurally diverse therapeutic candidates. Mitragyna speciosa Korth. contains bioactive indole alkaloids, particularly mitragynine and 7-hydroxymitragynine, that have been associated with anti-inflammatory effects. This study evaluated the predicted binding affinity and ligand-protein interaction profiles of mitragynine and 7-hydroxymitragynine against four inflammation-related targets—cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2), interleukin-1 beta (IL-1β), and tumor necrosis factor-alpha (TNF-α)—using molecular docking. Protein structures were obtained from the Protein Data Bank (PDB IDs 1EQG, 3LN1, 5R87, and 3EWJ, respectively). Protein and ligand preparation and interaction visualization were performed using Discovery Studio Visualizer, docking was conducted using PLANTS, and protocol validation was assessed by redocking and root mean square deviation (RMSD) analysis in Molegro Molecular Viewer. All protocols met the prespecified RMSD acceptance criterion of ≤2.0 Å, with values of 1.57 Å for COX-1, 0.77 Å for COX-2, 1.36 Å for IL-1β, and 0.55 Å for TNF-α. Within each protein target, 7-hydroxymitragynine showed the most favorable predicted score among the tested alkaloids for COX-1 and COX-2 (−17.39 and −19.56 kcal/mol, respectively), whereas mitragynine showed the more favorable predicted score for IL-1β and TNF-α (−16.72 and −20.42 kcal/mol, respectively). These results indicate target-dependent binding behavior and provide a computational basis for further structural, pharmacokinetic, and experimental evaluation of both alkaloids as potential anti-inflammatory candidates.
Downloads
Article Details

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med 2019;25:1822-1832. https://doi.org/10.1038/s41591-019-0675-0. DOI: https://doi.org/10.1038/s41591-019-0675-0
Pahwa R, Goyal A, Jialal I. Chronic inflammation. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK493173/ (accessed August 21, 2026).
Xiao F, Farag MA, Xiao J, Yang X, Liu Y, Shen J, et al. The influence of phytochemicals on cell heterogeneity in chronic inflammation-associated diseases: the prospects of single cell sequencing. J Nutr Biochem. 2022;108:109091. https://doi.org/10.1016/j.jnutbio.2022.109091. DOI: https://doi.org/10.1016/j.jnutbio.2022.109091
Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 2018;9:7204-7218. https://doi.org/10.18632/oncotarget.23208. DOI: https://doi.org/10.18632/oncotarget.23208
Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2018;38:e39-e46. https://doi.org/10.1161/ATVBAHA.117.310221. DOI: https://doi.org/10.1161/ATVBAHA.117.310221
Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev 2018;281:8-27. https://doi.org/10.1111/imr.12621. DOI: https://doi.org/10.1111/imr.12621
Vane JR, Botting RM. The mechanism of action of aspirin and other non-steroidal anti-inflammatory drugs. Lancet 2018;392:1015-1026. https://doi.org/10.1016/S0140-6736(18)31126-7. DOI: https://doi.org/10.1016/S0140-6736(18)31126-7
Tai FWD, McAlindon ME. Non-steroidal anti-inflammatory drugs and the gastrointestinal tract. Clin Med (Lond) 2021;21:131-134. https://doi.org/10.7861/clinmed.2021-0039. DOI: https://doi.org/10.7861/clinmed.2021-0039
Schjerning AM, McGettigan P, Gislason G. Cardiovascular effects and safety of (non-aspirin) NSAIDs. Nat Rev Cardiol 2020;17:574-584. https://doi.org/10.1038/s41569-020-0366-z. DOI: https://doi.org/10.1038/s41569-020-0366-z
Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis. Rheumatol Ther 2016;3:1-12. https://doi.org/10.1007/s40744-016-0021-9.
Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov 2021;20:200-216. https://doi.org/10.1038/s41573-020-00114-z. DOI: https://doi.org/10.1038/s41573-020-00114-z
Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod 2020;83:770-803. https://doi.org/10.1021/acs.jnatprod.9b01285. DOI: https://doi.org/10.1021/acs.jnatprod.9b01285
Hanapi NA, Chear NJY, Azizi J, Yusof SR. Kratom alkaloids: interactions with enzymes, receptors, and cellular barriers. Front Pharmacol 2021;12:751656. https://doi.org/10.3389/fphar.2021.751656. DOI: https://doi.org/10.3389/fphar.2021.751656
Prozialeck WC, Avery BA, Váradi A, Schwartz PA, Fantegrossi WE. Pharmacological and toxicological effects of kratom: a systematic review. J Pharmacol Exp Ther 2019;371:1-14. https://doi.org/10.1124/jpet.119.258269.
Kamble SH, Sharma A, King TI, Berthold EC, Leon F, Avery BA, et al. Metabolism of mitragynine to 7-hydroxymitragynine and its contribution to the pharmacological activity of kratom. J Med Chem 2019;62:1060-1073. https://doi.org/10.1021/acs.jmedchem.8b01419.
Hassan Z, Muzaimi M, Navaratnam V, Yusoff NHM, Suhaimi FW, Vadivelu R, et al. From kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse and addiction. Neurosci Biobehav Rev 2013;37:138-151. https://doi.org/10.1016/j.neubiorev.2012.11.012. DOI: https://doi.org/10.1016/j.neubiorev.2012.11.012
Kruegel AC, Uprety R, Grinnell SG, Langreck C, Pekarskaya EA, Le Rouzic V, et al. 7-Hydroxymitragynine is an active metabolite of mitragynine and a potent opioid agonist. J Am Chem Soc 2019;141:1610-1619. https://doi.org/10.1021/jacs.8b12304. DOI: https://doi.org/10.26434/chemrxiv.7692710.v1
Leong Bin Abdullah MFI, Singh D. The adverse cardiovascular effects and cardiotoxicity of kratom (Mitragyna speciosa Korth.): a comprehensive review. Front Pharmacol 2021;12:726003. https://doi.org/10.3389/fphar.2021.726003. DOI: https://doi.org/10.3389/fphar.2021.726003
Vicknasingam B, Narayanan S, Ramanathan S, et al. Kratom use and its relationship with pain and inflammatory conditions: current pharmacological evidence. J Ethnopharmacol 2020;250:112448. https://doi.org/10.1016/j.jep.2019.112448.
Karunakaran T, Sahayam S, Mohamed Z, et al. The chemical and pharmacological properties of mitragynine and its diastereomers: an insight review. Front Pharmacol 2022;12:805986. https://doi.org/10.3389/fphar.2021.805986. DOI: https://doi.org/10.3389/fphar.2022.805986
Swogger MT, Walsh Z. Kratom use and mental health: a systematic review. Drug Alcohol Depend 2018;186:116-124. https://doi.org/10.1016/j.drugalcdep.2018.01.013. DOI: https://doi.org/10.1016/j.drugalcdep.2018.01.013
Pinzi L, Rastelli G. Molecular docking: shifting paradigms in drug discovery. Int J Mol Sci 2019;20:433. https://doi.org/10.3390/ijms20020433. DOI: https://doi.org/10.3390/ijms20184331
Ferreira LG, Dos Santos RN, Oliva G, Andricopulo AD. Molecular docking and structure-based drug design strategies. Molecules 2015;20:13384-13421. https://doi.org/10.3390/molecules200713384. DOI: https://doi.org/10.3390/molecules200713384
Grundmann O. Patterns of kratom use and health impact in the United States: a systematic review. J Psychoactive Drugs 2017;49:279-288. https://doi.org/10.1080/02791072.2017.1314039.
Prozialeck WC, Jivan JK, Andurkar SV. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. J Am Osteopath Assoc 2012;112:792-799. https://doi.org/10.7556/jaoa.2012.112.12.792.
Annuar NAK, Azlan UK, Mediani A, Tong X, Han R, Al-Olayan E, et al. An insight review on the neuropharmacological effects, mechanisms of action, pharmacokinetics and toxicity of mitragynine. Biomed Pharmacother. 2024;171:116134. https://doi.org/10.1016/j.biopha.2024.116134. DOI: https://doi.org/10.1016/j.biopha.2024.116134
Tuntiyasawasdikul S, Junlatat J, Tabboon P, Limpongsa E, Jaipakdee N. Mitragyna speciosa ethanolic extract: extraction, anti-inflammatory, cytotoxicity, and transdermal delivery assessments. Ind Crops Prod. 2024;208:117909. https://doi.org/10.1016/j.indcrop.2023.117909. DOI: https://doi.org/10.1016/j.indcrop.2023.117909
Rahmawati SI, Indriani DW, Ningsih FN, Hardhiyuna M, Firdayani F, Ahmadi P, et al. Dual anti-inflammatory activities of COX-2/5-LOX driven by kratom alkaloid extracts in lipopolysaccharide-induced RAW 264.7 cells. Sci Rep. 2024;14:28993. https://doi.org/10.1038/s41598-024-79229-x. DOI: https://doi.org/10.1038/s41598-024-79229-x
Mahaprom K, Chokpaisarn J, Kunworarath N, Paduka W, Phoopha S, Limsuwan S, et al. In vivo analgesic, anti-inflammatory activities, and phytochemical profile of Thai herbal Kratom recipe, a traditional Thai herbal medicine for muscle pain relief. J Ethnopharmacol. 2025;343:119442. https://doi.org/10.1016/j.jep.2025.119442. DOI: https://doi.org/10.1016/j.jep.2025.119442